Celsion's EGEN Acquisition Brings Immunotherapy And RNA Therapeutics To Its Cancer Platform by Sharon di Stefano
This article was published on Tue, Jul. 22, 1:29 PM ET
INVESTMENT OPINION We are reiterating our BUY rating of Celsion Corporation and our 12-month target price of $8, based on a comparables analysis of similarly staged, platform based biotechnology companies. We recently had the opportunity to obtain an in-person update from Celsion’s management team, including Dr. Khursheed Anwar, who joined Celsion with the recent acquisition of EGEN, Inc. In our conversation, we learned what separates EGEN’s platform technologies for delivery and expression of nucleic acids from competitors. Going forward, we believe certain EGEN assets, in particular the TheraSilence platform and EGEN-001, could translate into value drivers for the combined entity. With the pending OPTIMA Phase 3 initiation, a strategic acquisition which added immuno-oncology and RNAi programs, and approximately $53.8 MM in cash for clinical development, we believe Celsion represents an undervalued player with significant upside for the long-term, risk-tolerant investor.
Sentiment: Strong Buy
No matter how many thumbs UP you give yourself biophamr, and how many thumbs DOWN you give me, what's going to happen is going to happen. Historically, we both know who's been most accurate with stock price calls, fundraisers, reverse splits, and Phase III failure warnings.
My only advise to ostrich pump dudes is do NOT bet your life savings here.
They simply can't move forward in a meaningful way without significant inflows of cash.
Fundraisers mean D I L U T I O N
Sorry pump dudes, without an incredible surprise announcement, this appears headed much lower.
RCW news due this fall, 2014. If successful, large move north.
Phase 1 metastasis trial will produce news in the not too distant future. (not going to look it up)
Of course, the Optima will be a couple of years before the DMC meets. Who knows what that will entail.
It's sunny skies ahead for Celsion.
We won't be so petty as to taunt you d-bags. You can just ruminate in your own poo for all we care.
1. what are the projected annual gross revenues?
2. what is the projected net PROFIT from those gross revenues?
3. what level of officers compensation does that product line financially support and justify?
within 2 years they will. price target in my opinion $24.00.